Traws Pharma Inc's Comment on Sales, Marketing and Customers
The company operates in the pharmaceutical sector, focusing on treatments for influenza and COVID-19. Notable drugs in this market include oseltamivir phosphate (Tamiflu) by Gilead, zanamivir (Relenza) by GlaxoSmithKline (GSK), peramivir (Rapivab) by BioCryst partners, baloxavir marboxil (Xofluza) by Roche, remdesivir by Gilead, oral Paxlovid by Pfizer, and oral molnupiravir by Merck and Ridgeback. Competitors developing anti-influenza drugs include Cidara and Eradivir. In the metastatic breast cancer market, companies marketing CDK 4/6 inhibitors include Pfizer, Novartis, and Eli Lilly. The company’s manufacturing is conducted through third-party contract manufacturers under quality agreements and in compliance with FDA current Good Manufacturing Practice (cGMP) standards. Customers and markets referenced include BioCryst partners, Cidara, Eli Lilly, Eradivir, Gilead, GlaxoSmithKline (GSK), Merck, Novartis, Pfizer, Ridgeback, and Roche.
: Traws Pharma, Inc. has unveiled significant progress in its antiviral bird flu program, announcing positive topline results from a pivotal study utilizing tivoxavir marboxil (TXM). This investigational oral small molecule, designed to inhibit CAP-dependent endonucleases, demonstrates potential as a single-dose treatment against H5N1 avian influenza in non-human primates. This study represents a critical advancement in the ongoing battle against respiratory viral diseases, highlighting the therapeutic potential of TXM in both avian and seasonal influenza contexts.Bird flu, specifically H5N1, remains a critical threat to global health, posing risks to both avian and human populations. With increasing instanc...
In a rapidly evolving biopharmaceutical sector, Traws Pharma, Inc. has emerged as a notable player, particularly within the sphere of oral therapeutics for respiratory viral diseases. The company, headquartered in Newtown, Pennsylvania, recently provided a comprehensive business update and unveiled its financial results for the third quarter of 2024. As Traws Pharma continues to develop cutting-edge treatments, its latest advancements signal not only progress in clinical efficacy but also a broader potential impact on public health, particularly amidst ongoing concerns surrounding respiratory viral outbreaks.As of November 14, 2024, Traws Pharma reported several key developments that underscore its strategic...
: The pharmaceutical landscape has been profoundly impacted by the emergence of COVID-19, necessitating rapid innovation in antiviral therapies. Traws Pharma’s recent announcement regarding the topline results from a Phase 1 clinical trial offers significant insights into the therapeutic potential of Ratutrelvir, an oral Mpro inhibitor aimed at combating COVID-19. This article reviews the key findings from the study, highlights the drug’s pharmacokinetics, tolerability, and therapeutic implications in the ongoing battle against the pandemic. COVID-19, caused by the SARS-CoV-2 virus, continues to pose a global health threat, prompting extensive research into effective antiviral treatments. Among the pr...
Traws Pharma Inc’s Comment on Sales, Marketing and Customers
The company operates in the pharmaceutical sector, focusing on treatments for influenza and COVID-19. Notable drugs in this market include oseltamivir phosphate (Tamiflu) by Gilead, zanamivir (Relenza) by GlaxoSmithKline (GSK), peramivir (Rapivab) by BioCryst partners, baloxavir marboxil (Xofluza) by Roche, remdesivir by Gilead, oral Paxlovid by Pfizer, and oral molnupiravir by Merck and Ridgeback. Competitors developing anti-influenza drugs include Cidara and Eradivir. In the metastatic breast cancer market, companies marketing CDK 4/6 inhibitors include Pfizer, Novartis, and Eli Lilly. The company’s manufacturing is conducted through third-party contract manufacturers under quality agreements and in compliance with FDA current Good Manufacturing Practice (cGMP) standards. Customers and markets referenced include BioCryst partners, Cidara, Eli Lilly, Eradivir, Gilead, GlaxoSmithKline (GSK), Merck, Novartis, Pfizer, Ridgeback, and Roche.
Sources:
Traws Pharma inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Traws Pharma inc’s corporate clients.
For your research, we’ve provided 9 tables on Traws Pharma inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
